![bRo5: Macrocyclics, Degraders, & More Icon](/images/librariesprovider23/agenda/23/icon_mcy.png)
Cambridge Healthtech Institute’s 2nd Annual
bRo5: Macrocyclics, Degraders & More
Designing Drug-Like Large Molecules beyond the Rule of Five
APRIL 12 - 13, 2023
A new frontier for discovery chemists is designing larger molecules such as macrocyclics, constrained peptides, or bifunctional degraders for targeted protein degradation (TPD) applications, that are better able to combat difficult intracellular targets than are small molecules. The difficulty is for such compounds to retain the favorable drug properties of small molecules: oral bioavailability, solubility, and cell permeability. In other words, going beyond Lipinski’s rule of five is becoming a more common challenge. At Cambridge Healthtech Institute’s 2nd Annual bRo5 conference, join fellow medicinal, computational, and synthetic chemists to discuss success stories and survey the field to discuss strategies for addressing these newer ‘large small molecule’ drug modalities.